Haohua Chemical Science & Technology stock
600378.SSSHHHaohua Chemical Science & Technology Corp., Ltd., Basic MaterialsISIN CNE0000016V4
58Score 58 out of 100, Neutral
Price and trend
40 / 100
Price history
+2.0% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 21% below it.
Since November 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 43).
The price is 59% below its 52-week high. Largest decline in 20 years: 83% (October 2007 to November 2008).
Chart figures for advanced users
- SMA 50$6.12
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$6.33
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)43
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$4.36
- The lowest closing price of the last twelve months.
- Resistance$12.32
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Haohua Chemical Science & Technology Corp., Ltd. belongs to the Chemicals industry (China) and, with a market value of $6.45B, is number 21 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.5B (up 19.5% year on year) and earnings of $216.54M (up 37.1%).
- For fiscal 2026, analysts expect on average revenue of $2.87B (up 14.9%) and adjusted earnings per share of $0.22.
Show more
- MEQIRI Score 58 out of 100 (Neutral): rank 234 of 467 in Basic Materials, median 58.
- The P/E is 27.3 (Chemicals median 20.6, own median of recent years 30.3).
- Our model puts fair value at $3.28, with the price 54% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 25.2% a year since 2020, Chemicals median 14.2%.Growth 76
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 74
- Earnings turn into cashFree cash flow 149% of earnings over the last 12 months.Fundamentals 74
Weaknesses
- DilutionShare count up 44% since 2020.Capital allocation 40
- Volatile share priceVolatility 64% a year over the last 12 months.
Its standout strengths are growth and fundamentals, while technical analysis and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 57 to 58.
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Modestly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $2.18 and expensive above $6.55 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $2.78 (cash-flow model) and $3.78 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $3.03, at 6.3% it would be $3.66.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (20.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 20.2% on the twelve months before. Revenue has grown strongly since 2006, at around 22% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 25%, operating 11%, net 9%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 23 Apr 2027in 162 days
- Last reported
- 29 Oct 2026EPS reported $0.05
Analyst estimates
Analysts have cut their 2026 earnings estimate by 7.9% since 28 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.22−7.9%
- Revenue
- $2.87B+1.1%
- Earnings per share
- $0.28−4.4%
- Revenue
- $3.25B+1.9%
MEQIRI has stored the estimates since 28 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Haohua Chemical Science & Technology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
467 rated companies in Basic Materials
- This company
- 58
- Sector median
- 58
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Chemicals
The next larger and next smaller companies by market value
- Syensqo SA/NVSYENS.BR $9.08B54
- SasolSSL $9.03B58
- Shandong Hualu-Hengsheng Chemical600426.SS $7.86B62
- Ecopro086520.KQ $7.45B28
- Nissan Chemical4021.T $5.88B76
- CelaneseCE $5.65B52
- Tokyo Ohka Kogyo4186.T $5.61B68
- MethanexMEOH $5.34B73
ETFs that hold Haohua Chemical Science & Technology
Held by 20 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI China A UCITS ETF36BZ | 0.09% | 0.40% | €1.79B |
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.3B |
| HSBC MSCI China UCITS ETFH4ZP | 0.02% | 0.28% | €865.21M |
Show 5 more
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.00% | 0.17% | €5.24B |
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.00% | 0.18% | €37.17B |
| HSBC MSCI AC FAR EAST ex JAPAN UCITS ETF USDH411 | 0.00% | 0.45% | €400.29M |
| UBS Core MSCI EM UCITS ETF USD disUIMI | 0.00% | 0.15% | €10.33B |
| Xtrackers MSCI Emerging Markets UCITS ETF 1CXMME | 0.00% | 0.18% | €12.56B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CN¥6.6707)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Jun 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.